An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2019
At a glance
- Drugs PT 2977 (Primary)
- Indications Renal cell carcinoma; Von Hippel-Lindau disease
- Focus Therapeutic Use
- Sponsors Peloton Therapeutics
- 20 Mar 2018 Status changed from not yet recruiting to recruiting.
- 09 Mar 2018 Planned initiation date changed from 1 Mar 2018 to 19 Mar 2018.
- 27 Dec 2017 New trial record